Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jawed Fareed

Showing results (381-390 of 393) with videos related to

Pageof 40
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 23, 2025
Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent ClaudicationKaren Falcão Britto, Roberto Augusto Caffaro, Giuliano Giova Volpiani, et al.
JAMA|May 20, 2019
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical TrialJean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 7, 2022
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : <u>V</u>enous thromboembolism prophyl<u>A</u>xis after gyneco<u>L</u>ogical p<u>E</u>lvic cancer surgery with <u>RI</u>varoxaban versus enox<u>A</u>parin (VALERIA trial)André Luiz Malavasi Longo de Oliveira, Renata Fernanda de Oliveira Pereira, Leandro Barile Agati, et al.
International Angiology : a Journal of the International Union of Angiology|February 29, 2024
Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidenceAndrew N Nicolaides, Jawed Fareed, Alex C Spyropoulos, et al.
Critical Care Medicine|August 28, 2013
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulationJean-Louis Vincent, Mayakonda K Ramesh, David Ernest, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
Thrombosis and Haemostasis|February 5, 2024
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus PaperJob Harenberg, Robert C Gosselin, Adam Cuker, et al.
Thrombosis and Haemostasis|November 27, 2025
Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus PaperJob Harenberg, Robert C Gosselin, Adam Cuker, et al.
Lancet (London, England)|December 18, 2021
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trialEduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, et al.
Journal of the American College of Cardiology|April 21, 2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art ReviewBehnood Bikdeli, Mahesh V Madhavan, David Jimenez, et al.
Pageof 40

Showing results (381-390 of 393) with videos related to

Sort By:
Pageof 40
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 23, 2025
Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent ClaudicationKaren Falcão Britto, Roberto Augusto Caffaro, Giuliano Giova Volpiani, et al.
JAMA|May 20, 2019
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical TrialJean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 7, 2022
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : <u>V</u>enous thromboembolism prophyl<u>A</u>xis after gyneco<u>L</u>ogical p<u>E</u>lvic cancer surgery with <u>RI</u>varoxaban versus enox<u>A</u>parin (VALERIA trial)André Luiz Malavasi Longo de Oliveira, Renata Fernanda de Oliveira Pereira, Leandro Barile Agati, et al.
International Angiology : a Journal of the International Union of Angiology|February 29, 2024
Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidenceAndrew N Nicolaides, Jawed Fareed, Alex C Spyropoulos, et al.
Critical Care Medicine|August 28, 2013
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulationJean-Louis Vincent, Mayakonda K Ramesh, David Ernest, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
Thrombosis and Haemostasis|February 5, 2024
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus PaperJob Harenberg, Robert C Gosselin, Adam Cuker, et al.
Thrombosis and Haemostasis|November 27, 2025
Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus PaperJob Harenberg, Robert C Gosselin, Adam Cuker, et al.
Lancet (London, England)|December 18, 2021
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trialEduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, et al.
Journal of the American College of Cardiology|April 21, 2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art ReviewBehnood Bikdeli, Mahesh V Madhavan, David Jimenez, et al.
Pageof 40